Mazdutide: A Tracking Guide for a Glucagon and GLP-1 Dual Agonist

Mazdutide is a dual glucagon (GCG) and GLP-1 receptor agonist, structurally an oxyntomodulin analogue, developed by Innovent under license from Eli Lilly for the Chinese market. The GLP-1 arm suppresses appetite and lowers blood sugar, while the glucagon arm can raise energy expenditure and improve hepatic fat metabolism. In June 2025 China's NMPA approved mazdutide for chronic weight management, making it the first approved dual GCG/GLP-1 agonist, and a glycemic-control approval followed later in 2025.

This is an educational tracking guide, not medical advice or a recommendation. Note that mazdutide is approved in China but not in the US or EU.

What it does

• Combines glucagon and GLP-1 agonism for weight loss and glucose lowering
• Increases energy expenditure via glucagon receptor activation
• Reduces waist circumference, liver fat, blood lipids, and liver enzymes in studies

Typical protocol shape

In the Chinese trials and label, mazdutide is titrated upward over weeks to a maintenance dose to limit GI effects, given once weekly by subcutaneous injection, with a higher-dose option under review for more severe obesity. Doses here reflect the trial and label context only, not a recommendation.

What to track daily

• Appetite, portion sizes, and early fullness
• Nausea, vomiting, diarrhea, or constipation
• Resting heart rate

What to track weekly

• Bodyweight under consistent conditions
• Waist circumference
• Injection-site tolerance
• Grip strength or a simple lift to watch for muscle loss during rapid loss

Bloodwork worth doing

• Fasting glucose and HbA1c
• Lipid panel and liver enzymes, since the glucagon arm targets hepatic fat
• Note thyroid history given the GLP-1 class signal

Realistic expectations

Because the glucagon component can raise energy expenditure, the metabolic profile differs somewhat from pure GLP-1 drugs, but weight loss is still gradual and diet-dependent. Track lean mass indirectly through strength as part of any rapid loss phase.

Common mistakes

• Assuming Chinese approval means US availability or oversight
• Skipping protein and resistance work during weight loss
• Ignoring persistent GI symptoms or dehydration

Safety notes

Mazdutide's approval is specific to China; access elsewhere is off the regulated path. Expect GLP-1 class GI effects and the thyroid tumor signal that governs the class, plus the added consideration that glucagon agonism can affect glucose and heart rate. Use only with medical supervision and monitoring.

Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.